Neoadjuvant therapy of imatinib in gastrointestinal stromal tumors and the timing of surgery
10.3760/cma.j.issn.1671-0274.2015.04.004
- VernacularTitle:胃肠间质瘤的伊马替尼新辅助治疗及手术时机的选择
- Author:
Yinan SHI
1
;
Xiaobo LIANG
Author Information
1. 山西省肿瘤医院消化微创外科
- Keywords:
Gastrointestinal stromal tumors;
Neoadjuvant therapy;
Imatinib
- From:
Chinese Journal of Gastrointestinal Surgery
2015;(4):313-315
- CountryChina
- Language:Chinese
-
Abstract:
Imatinib is the key medication for adjuvant therapy in gastrointestinal stromal tumors (GIST) and the first line therapy for patients with metastatic or recurrent GIST. Preoperative treatment with imatinib may improve R0 resection rate and provide the chance of metastasectomy for cytoreduction as well as prolonging patient′s survival. We investigate the significance of neoadjuvant therapy of imatinib and the timing of surgery by reviewing clinical trials and consensus in recent years.
